Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

“We see that 57% of the patients are disease free after undergoing surgery, and the delta is about 9% when compared with the pembrolizumab arm,” he continued. Turning to prognostic markers, Bedke ...

Somewhat unusually, it said it would also like to see "more information from the company about the comparison between pembrolizumab plus chemotherapy with atezolizumab plus chemotherapy." ...

Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Lung cancer remains a leading cause of cancer-related deaths worldwide, demanding focused attention and unwavering commitment ...

2025年，全球医药领域将迎来一系列重要趋势和突破性进展。在肿瘤学、肥胖症药物以及人工智能（AI）应用的推动下，药物创新的格局正在被重新塑造，医疗健康产业也将面临前所未有的机遇与挑战。近期，《自然》旗下的Nature Reviews Drug ...

Future Oncol. 2015;11(7):1023-1026. Tumor-negative breast cancers misclassified as HER2 negative by IHC (0 or 1+) could therefore be reclassified by FISH, with a remarkable impact on medical ...

2025年，全球医药领域将迎来一系列重要趋势和突破性进展。在肿瘤学、肥胖症药物以及人工智能（AI）应用的推动下，药物创新的格局正在被重新塑造，医疗健康产业也将面临前所未有的机遇与挑战。近期，《自然》旗下的Nature Reviews Drug ...